ANDA 209869, held by Biocon Pharma. Pravastatin Sodium.
As of Nov 16, 2026, ANDA 209869 (Pravastatin Sodium), held by Biocon Pharma, was first approved by FDA on Apr 13, 2018, with 3 approved supplements and 0 published complete response letters.
Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Pravastatin Sodium is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 13, 2018 | Original application | Approved |
| Pravastatin Sodium10MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium20MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium40MG · tablet;oral | Pravastatin Sodium | Rx |
| Pravastatin Sodium80MG · tablet;oral | Pravastatin Sodium | Rx |
| Aug 5, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| Mar 27, 2023 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 29, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Apr 13, 2018 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters